The US Food and Drug Administration (FDA) has issued marketing clearance for Valeant Pharmaceuticals' Restylane Silk Injectable Gel with 0.3% Lidocaine, a device indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21. “We are pleased to have received marketing clearance from the FDA for Restylane Silk so quickly after the approval of Jublia,” said J. Michael Pearson, chairman and chie...